Erin A Hirsch1, Anna E Barón1, Betsy Risendal2, Jamie L Studts3, Melissa L New4, Stephen P Malkoski5. 1. Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado. 2. Department of Community and Behavioral Health, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado. 3. Division of Medical Oncology and Cancer Prevention and Control Program, University of Colorado Anschutz Medical Campus, Aurora, Colorado. 4. Pulmonary Section, Rocky Mountain Regional VA Medical Center, Aurora, Colorado; Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado. 5. Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado; Department of Medicine, University of Washington, WWAMI-Spokane, Spokane, Washington; Sound Critical Care, Sacred Heart Medical Center, Spokane, Washington. Electronic address: Stephen.Malkoski@cuanschutz.edu.
Abstract
OBJECTIVE: Lung cancer screening (LCS) efficacy is highly dependent on adherence to annual screening, but little is known about real-world adherence determinants. We used insurance claims data to examine associations between LCS annual adherence and demographic, comorbidity, health care usage, and geographic factors. MATERIALS AND METHODS: Insurance claims data for all individuals with an LCS low-dose CT scan were obtained from the Colorado All Payer Claims Dataset. Adherence was defined as a second claim for a screening CT 10 to 18 months after the index claim. Cox proportional hazards regression was used to define the relationship between annual adherence and age, gender, insurance type, residence location, outpatient health care usage, and comorbidity burden. RESULTS: After exclusions, the final data set consisted of 9,056 records with 3,072 adherent, 3,570 nonadherent, and 2,414 censored (unclassifiable) individuals. Less adherence was associated with ages 55 to 59 (hazard ratio [HR] = 0.80, 99% confidence interval [CI] = 0.67-0.94), 60 to 64 (HR = 0.83, 99% CI = 0.71-0.97), and 75 to 79 (HR = 0.79, 99% CI = 0.65-0.97); rural residence (HR = 0.56, 99% CI = 0.43-0.73); Medicare fee-for-service (HR = 0.45, 99% CI = 0.39-0.51), and Medicaid (HR = 0.50, 99% CI = 0.40-0.62). A significant interaction between outpatient health care usage and comorbidity was also observed. Increased outpatient usage was associated with increased adherence and was most pronounced for individuals without comorbidities. CONCLUSIONS: This population-based description of LCS adherence determinants provides insight into populations that might benefit from specific interventions targeted toward improving adherence and maximizing LCS benefit. Quantifying population-based adherence rates and understanding factors associated with annual adherence are critical to improving screening adherence and reducing lung cancer death.
OBJECTIVE: Lung cancer screening (LCS) efficacy is highly dependent on adherence to annual screening, but little is known about real-world adherence determinants. We used insurance claims data to examine associations between LCS annual adherence and demographic, comorbidity, health care usage, and geographic factors. MATERIALS AND METHODS: Insurance claims data for all individuals with an LCS low-dose CT scan were obtained from the Colorado All Payer Claims Dataset. Adherence was defined as a second claim for a screening CT 10 to 18 months after the index claim. Cox proportional hazards regression was used to define the relationship between annual adherence and age, gender, insurance type, residence location, outpatient health care usage, and comorbidity burden. RESULTS: After exclusions, the final data set consisted of 9,056 records with 3,072 adherent, 3,570 nonadherent, and 2,414 censored (unclassifiable) individuals. Less adherence was associated with ages 55 to 59 (hazard ratio [HR] = 0.80, 99% confidence interval [CI] = 0.67-0.94), 60 to 64 (HR = 0.83, 99% CI = 0.71-0.97), and 75 to 79 (HR = 0.79, 99% CI = 0.65-0.97); rural residence (HR = 0.56, 99% CI = 0.43-0.73); Medicare fee-for-service (HR = 0.45, 99% CI = 0.39-0.51), and Medicaid (HR = 0.50, 99% CI = 0.40-0.62). A significant interaction between outpatient health care usage and comorbidity was also observed. Increased outpatient usage was associated with increased adherence and was most pronounced for individuals without comorbidities. CONCLUSIONS: This population-based description of LCS adherence determinants provides insight into populations that might benefit from specific interventions targeted toward improving adherence and maximizing LCS benefit. Quantifying population-based adherence rates and understanding factors associated with annual adherence are critical to improving screening adherence and reducing lung cancer death.
Authors: Harry J de Koning; Carlijn M van der Aalst; Pim A de Jong; Ernst T Scholten; Kristiaan Nackaerts; Marjolein A Heuvelmans; Jan-Willem J Lammers; Carla Weenink; Uraujh Yousaf-Khan; Nanda Horeweg; Susan van 't Westeinde; Mathias Prokop; Willem P Mali; Firdaus A A Mohamed Hoesein; Peter M A van Ooijen; Joachim G J V Aerts; Michael A den Bakker; Erik Thunnissen; Johny Verschakelen; Rozemarijn Vliegenthart; Joan E Walter; Kevin Ten Haaf; Harry J M Groen; Matthijs Oudkerk Journal: N Engl J Med Date: 2020-01-29 Impact factor: 91.245
Authors: Uraujh Yousaf-Khan; Carlijn van der Aalst; Pim A de Jong; Marjolein Heuvelmans; Ernst Scholten; Jan-Willem Lammers; Peter van Ooijen; Kristiaan Nackaerts; Carla Weenink; Harry Groen; Rozemarijn Vliegenthart; Kevin Ten Haaf; Matthijs Oudkerk; Harry de Koning Journal: Thorax Date: 2016-06-30 Impact factor: 9.139
Authors: Amy Duncan; Deborah Turnbull; Carlene Wilson; Joanne M Osborne; Stephen R Cole; Ingrid Flight; Graeme P Young Journal: BMC Public Health Date: 2014-03-07 Impact factor: 3.295
Authors: Phil A Crosbie; Haval Balata; Matthew Evison; Melanie Atack; Val Bayliss-Brideaux; Denis Colligan; Rebecca Duerden; Josephine Eaglesfield; Timothy Edwards; Peter Elton; Julie Foster; Melanie Greaves; Graham Hayler; Coral Higgins; John Howells; Klaus Irion; Devinda Karunaratne; Jodie Kelly; Zoe King; Judith Lyons; Sarah Manson; Stuart Mellor; Donna Miller; Amanda Myerscough; Tom Newton; Michelle O'Leary; Rachel Pearson; Julie Pickford; Richard Sawyer; Nick J Screaton; Anna Sharman; Maggi Simmons; Elaine Smith; Ben Taylor; Sarah Taylor; Anna Walsham; Angela Watts; James Whittaker; Laura Yarnell; Anthony Threlfall; Phil V Barber; Janet Tonge; Richard Booton Journal: Thorax Date: 2018-11-12 Impact factor: 9.139
Authors: Roger Y Kim; Katharine A Rendle; Nandita Mitra; Chelsea A Saia; Christine Neslund-Dudas; Robert T Greenlee; Andrea N Burnett-Hartman; Stacey A Honda; Michael J Simoff; Marilyn M Schapira; Jennifer M Croswell; Rafael Meza; Debra P Ritzwoller; Anil Vachani Journal: Ann Am Thorac Soc Date: 2022-09